Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus...
Kexing Biopharma (SHA: 688136) announced it has received approval from the U.S. Food and Drug...
Kexing Biopharm Co., Ltd. (SHA: 688136) announced clinical trial approval from China’s National Medical Products Administration...
Kexing Biopharma (SHA: 688136) announced that China’s National Medical Products Administration (NMPA) has cleared GB19 Injection...
Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...
China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...
On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...
China-based Kexing Pharmaceutical (SHA: 688136) announced that it has received approval from the National Medical...
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...
China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...
China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...